Sunday 18 October 2026
Export PBLS’s income statement to Excel — free account
Parabilis Medicines, Inc.
PBLS
Insiders bought in the last twelve months.
22.75
2.43
−9.65%
Follow PBLS
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
2.84 | 0.52 |
Net Debt/EBITDA |
0.57 | 0.09 |
Debt/Assets |
11.66% | 18.00% |
Debt/Equity |
0.31 | (0.88) |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.64 | 0.66 |
Capex/Depreciation |
(0.59) | (0.10) |
Interest Coverage |
(84.88) | (99.92) |
| 0.00% | 41.06% | |
| 0.00% | (162.50%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(235.19%) | 902.27% |
Average Days of Receivables |
0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(54.02) | (61.30) |
Cash per Share |
45.48 | 13.70 |
Shareholders Equity per Share |
29.18 | (8.17) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
29.18 | (8.17) |
Free Cash Flow |
(104.49) | (124.02) |
Working Capital |
59.80 | (27.43) |
Capital Expenditures |
(0.88) | (0.31) |
Net Current Asset Value |
(0.61) | (67.99) |
| Other line items | ||
Quick Ratio |
2.72 | 0.49 |
Depreciation/Fixed assets |
0.17 | 0.46 |
Cash ROIC |
(64.58%) | (481.93%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(53.57) | (61.15) |
Capex per Share |
(0.45) | (0.15) |
Average Payables |
— | 13.39 |
Average Assets |
— | 115.04 |
Average Common Equity |
— | (455.22) |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026